Showing 1 - 5 results of 5 for search 'Hyung Don Kim', query time: 0.02s
Refine Results
-
1
-
2
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospec... by Jaekyung Cheon, Shigeo Shimose, Hyung-Don Kim, Takashi Niizeki, Min-Hee Ryu, Tomotake Shirono, Baek-Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo
Published 2025-01-01Get full text
Article -
3
Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma by Jiwon Yang, Won-Mook Choi, Hyung-Don Kim, Jonggi Choi, Changhoon Yoo, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee
Published 2024-10-01Get full text
Article -
4
Type 17 immunity promotes the exhaustion of CD8+ T cells in cancer by Chang-Yuil Kang, Eui-Cheol Shin, Yoon Kyung Jeon, Young-Jun Park, Chen Dong, Hye Young Kim, Byung-Seok Kim, Da-Sol Kuen, Choong-Hyun Koh, Hyung-Don Kim, Seon Hee Chang, Sehui Kim, Garam Choi, Jiyeon Kim, Keon Wook Kang, Suk-Jo Kang, Shin Hwang, Yeonseok Chung
Published 2021-06-01Get full text
Article -
5
Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation by Kyunghye Bang, Andrea Casadei‐Gardini, Changhoon Yoo, Massimo Iavarone, Min‐Hee Ryu, Sook Ryun Park, Hyung‐Don Kim, Young‐In Yoon, Dong‐Hwan Jung, Gil‐Chun Park, Chul‐Soo Ahn, Deok‐Bog Moon, Shin Hwang, Ki‐Hun Kim, Gi‐Won Song, Chiara Mazzarelli, Eleonora Alimenti, Stephen L. Chan, Massimo De Giorgio, Baek‐Yeol Ryoo, Sung‐Gyu Lee
Published 2023-02-01Get full text
Article